SPC Financial Inc. Sells 357 Shares of Hologic, Inc. (NASDAQ:HOLX)

SPC Financial Inc. trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 2.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,925 shares of the medical equipment provider’s stock after selling 357 shares during the quarter. SPC Financial Inc.’s holdings in Hologic were worth $860,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. General Partner Inc. purchased a new position in Hologic in the fourth quarter worth about $26,000. Groupama Asset Managment lifted its stake in shares of Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 2,999 shares during the period. Venturi Wealth Management LLC boosted its holdings in shares of Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 261 shares during the last quarter. First Horizon Advisors Inc. grew its position in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares during the period. Finally, Smartleaf Asset Management LLC increased its holdings in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 159 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley cut their price objective on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. UBS Group upped their price target on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Leerink Partners downgraded Hologic from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $80.00 to $75.00 in a research note on Thursday, February 6th. Stephens reiterated an “overweight” rating and set a $84.00 price objective on shares of Hologic in a research note on Thursday, February 6th. Finally, Argus cut shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Trading Down 1.5 %

Shares of Hologic stock opened at $62.30 on Wednesday. Hologic, Inc. has a twelve month low of $62.28 and a twelve month high of $84.67. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The business has a 50-day moving average price of $68.77 and a 200-day moving average price of $75.64. The firm has a market cap of $13.98 billion, a price-to-earnings ratio of 19.65, a PEG ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.